Gut Microbiota Dysbiosis in Suspected Food Protein Induced Proctocolitis-A Prospective Comparative Cohort Trial

Philipp Wurm1, Laura Stampfer2, Theresa Greimel2

  • 1From Institute of Pathology, Medical University of Graz, Graz, Austria.

Insights

Infants with suspected food protein-induced proctocolitis (sFPIP) show gut microbiota dysbiosis. Diagnostic dietary intervention (DDI) normalizes gut bacteria, suggesting dysbiosis may cause sFPIP symptoms like hematochezia.

Area of Science:

  • Microbiome research
  • Pediatric gastroenterology
  • Immunology

Background:

  • Suspected food protein-induced proctocolitis (sFPIP) diagnosis is challenging, with many infants not confirmed after diagnostic dietary intervention (DDI).
  • Hematochezia in infants with sFPIP lacks a clear pathophysiological explanation.
  • Understanding the gut microbiome's role in sFPIP is crucial for accurate diagnosis and management.

Purpose of the Study:

  • To investigate the gut microbiota composition in infants with sFPIP compared to healthy controls.
  • To determine if DDI alters the gut microbiota in infants with sFPIP.
  • To explore the potential link between gut dysbiosis and hematochezia in sFPIP.

Main Methods:

  • Prospective study comparing sFPIP infants and healthy controls.
  • 16S rRNA and shotgun metagenomic sequencing of fecal samples.
  • Analysis of microbial composition using Qiime2, DADA2, KneadData, and MetaPhlAn2.

Main Results:

  • sFPIP infants exhibited significant differences in gut microbial composition compared to controls at baseline.
  • Healthy infants showed higher abundance of Bifidobacterium, while sFPIP infants had increased Clostridium sensu stricto 1.
  • DDI led to a sustained increase in Bifidobacterium in sFPIP infants, normalizing their microbiota.

Conclusions:

  • Gut microbiota dysbiosis is a key feature in infants with sFPIP.
  • DDI effectively modulates the gut microbiota towards a healthy composition in sFPIP infants.
  • Gut dysbiosis is a likely trigger for hematochezia in the majority of sFPIP infants.
Abstract

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
379
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
210
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
237
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
340
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
498
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
325